The Medicines Company Up On Acquisition News

Barron's Take Health ALNY MDCO NOVN.EB Alnylam's The Medicines Novartis Biotechnology Pharmaceuticals Health Care/Life Sciences Biopharmaceuticals Joseph Schwartz Corporate Strategy/Planning Financial Performance Share Price Movement/Disruptions Ownership Changes Acquisitions/Mergers/Shareholdings Acquisitions/Mergers Corporate Actions Corporate/Industrial News Corporate Due Diligence Content Types Factiva Filters C&E Exclusion Filter C&E Industry News Filter I/BTC I/DRG M/HCR MDCO N/CAC N/CNW N/PFM N/TNM NOVN.EB NVS Barrons.com Barrons Blogs CODES_REVIEWED Companies Health Barron's Take US author Josh Nathan-Kazis author|Josh Nathan-Kazis author Josh Nathan-Kazis id Josh Nathan-Kazis name Josh Nathan-Kazis topicid 8583 rank 1 topicid barrons_display_brand BARTAKE barrons_display_brand|BARTAKE codetype BARRONS_DISPLAY_BRAND name Barron's Take source MANUAL value BARTAKE code BARTAKE canbedisplaybrand true status modified barrons_display_subject BARHEALTH barrons_display_subject|BARHEALTH canbedisplaysubject true codetype BARRONS_DISPLAY_SUBJECT name Health source MANUAL value BARHEALTH code BARHEALTH status modified co medcco co|medcco country US symbol MDCO codetype co displayname Medicines why about extractedtext The Medicines source FACTIVA occurs true seoname medicines name The Medicines orgtype public countrycode US relevancerange high chartingsymbol STOCK/US/XNAS/MDCO fcode medcco fullextractedtext The Medicines Company ticker MDCO confidence 100 subcat com code medcco relevance 97 significance prominent onlinesignificance prominent confidencerange high exchange Nasdaq exchangeisocode XNAS co sndoz co|sndoz country US symbol NOVN.EB codetype co displayname Novartis why about extractedtext Novartis source FACTIVA occurs true seoname novartis name Novartis orgtype public countrycode US relevancerange high chartingsymbol STOCK/US/XNYS/NVS fcode sndoz fullextractedtext Novartis ticker NVS confidence 100 subcat com code sndoz relevance 75 significance prominent onlinesignificance prominent confidencerange high exchange NYSE exchangeisocode XNYS co ALNYPH co|ALNYPH symbol ALNY country US codetype co displayname Alnylam Pharmaceuticals extractedtext Alnylam's source MANUAL code alny name Alnylam's significance prominent onlinesignificance passing-mention exchange U.S.: Nasdaq exchangeisocode XNAS chartingsymbol STOCK/US/XNAS/ALNY fcode ALNYPH status modified company NOVN.EB company|NOVN.EB name Novartis significance PASSING-MENTION company MDCO company|MDCO name The Medicines significance PROMINENT company ALNY company|ALNY name Alnylam’s significance PASSING-MENTION djn MDCO djn|MDCO codetype djn why about source FACTIVA occurs true code mdco name MDCO significance prominent onlinesignificance prominent fcode MDCO djn NOVN.EB djn|NOVN.EB codetype djn why about source FACTIVA occurs true code novn_eb name NOVN.EB significance prominent onlinesignificance prominent fcode NOVN.EB djn NVS djn|NVS codetype djn why about source FACTIVA occurs true code nvs name NVS significance prominent onlinesignificance prominent fcode NVS djn I/DRG djn|I/DRG codetype djn why about source FACTIVA code i_drg name I/DRG significance prominent onlinesignificance prominent fcode I/DRG djn I/BTC djn|I/BTC codetype djn why about source FACTIVA code i_btc name I/BTC significance prominent onlinesignificance prominent fcode I/BTC djn M/HCR djn|M/HCR codetype djn name M/HCR why lineage source FACTIVA code m_hcr fcode M/HCR djn N/PFM djn|N/PFM codetype djn why about source FACTIVA code n_pfm name N/PFM significance prominent onlinesignificance prominent fcode N/PFM djn N/CAC djn|N/CAC codetype djn why about source FACTIVA code n_cac name N/CAC significance prominent onlinesignificance prominent fcode N/CAC djn N/TNM djn|N/TNM codetype djn why about source FACTIVA code n_tnm name N/TNM significance prominent onlinesignificance prominent fcode N/TNM status modified djn N/CNW djn|N/CNW codetype djn why about source FACTIVA code n_cnw name N/CNW significance prominent onlinesignificance prominent fcode N/CNW editorial-seo-id the-medicines-company-stock-report-novartis-acquisition-51574177152 editorial-seo-id|the-medicines-company-stock-report-novartis-acquisition-51574177152 first_publish_headline The Medicines Company Stock Is Soaring Because Novartis Might Want to Buy It first_publish_headline|The Medicines Company Stock Is Soaring Because Novartis Might Want to Buy It flow Barrons.com flow|Barrons.com codetype FLOW name Barrons.com source MANUAL value Barrons.com code online status modified name Online title Product code Barrons.com flow Barrons Blogs flow|Barrons Blogs codetype FLOW source MANUAL title Product code Barrons_Blogs name Barrons Blogs value Barrons Blogs status modified headline The Medicines Company Stock Is Soaring Because Novartis Might Want to Buy It headline|The Medicines Company Stock Is Soaring Because Novartis Might Want to Buy It id facebook id|facebook news_tab_url https://www.barrons.com/articles/the-medicines-company-stock-report-novartis-acquisition-51574177152 in i257 in|i257 codetype in why about source FACTIVA code i257 name Pharmaceuticals significance prominent onlinesignificance prominent fcode i257 in i2569 in|i2569 codetype in why about source FACTIVA code i2569 name Biotechnology significance prominent onlinesignificance prominent fcode i2569 in i951 in|i951 codetype in name Health Care/Life Sciences why lineage source FACTIVA code i951 fcode i951 in ibioph in|ibioph codetype in name Biopharmaceuticals why association source FACTIVA code ibioph fcode ibioph media media-2 media|media-2 responsive layout wrap softcrop Horizontal imphotoid im-128352 location https://images.barrons.com/im-128352/?size=1.5 media media-1 media|media-1 softcrop Horizontal imphotoid im-128352 location https://images.barrons.com/im-128352/?size=1.5 ns c1522 ns|c1522 codetype ns why about source FACTIVA code c1522 name Share Price Movement/Disruptions significance prominent onlinesignificance prominent fcode c1522 ns c15 ns|c15 codetype ns why about source FACTIVA code c15 name Financial Performance significance prominent onlinesignificance prominent fcode c15 ns cactio ns|cactio codetype ns why about source FACTIVA code cactio name Corporate Actions significance prominent onlinesignificance prominent fcode cactio ns c181 ns|c181 codetype ns why about source FACTIVA code c181 name Acquisitions/Mergers/Shareholdings significance prominent onlinesignificance prominent fcode c181 ns c18 ns|c18 codetype ns why about source FACTIVA code c18 name Ownership Changes significance prominent onlinesignificance prominent fcode c18 ns cdued ns|cdued codetype ns why about source FACTIVA code cdued name Corporate Due Diligence significance prominent onlinesignificance prominent fcode cdued ns cacqu ns|cacqu codetype ns why about source FACTIVA code cacqu name Acquisitions/Mergers significance prominent onlinesignificance prominent fcode cacqu ns ccat ns|ccat codetype ns why about source FACTIVA code ccat name Corporate/Industrial News significance prominent onlinesignificance prominent fcode ccat ns c11 ns|c11 codetype ns name Corporate Strategy/Planning why lineage source FACTIVA code c11 fcode c11 ns ncat ns|ncat codetype ns why lineage source FACTIVA code ncat name Content Types internalsymbol true fcode ncat ns nfact ns|nfact codetype ns why lineage source FACTIVA code nfact name Factiva Filters internalsymbol true fcode nfact ns nfce ns|nfce codetype ns why lineage source FACTIVA code nfce name C&E Exclusion Filter internalsymbol true fcode nfce ns nfcpin ns|nfcpin codetype ns why lineage source FACTIVA code nfcpin name C&E Industry News Filter internalsymbol true fcode nfcpin nwchain SB523555383061663141638045860277935161174561 nwchain|SB523555383061663141638045860277935161174561 pe Joseph Schwartz pe|Joseph Schwartz lastname Schwartz codetype pe displayname Schwartz, Joseph extractedtext Joseph Schwartz source FACTIVA code joseph_schwartz name Joseph Schwartz firstname Joseph nameformat surname_first relay SYND relay|SYND codetype RELAY name Syndication source EXPANDER value SYND code synd status modified statistic CODES_REVIEWED statistic|CODES_REVIEWED name CODES_REVIEWED value CODES_REVIEWED codetype STATISTIC code CODES_REVIEWED subject BARCOMP subject|BARCOMP codetype SUBJECT title Companies code BARCOMP name Companies canbedisplaysubject true ruleid BARCOMP value BARCOMP status modified subject BARUS subject|BARUS codetype SUBJECT title US code BARUS name US canbedisplaysubject true ruleid BARUS value BARUS status modified subject BARHEALTH subject|BARHEALTH codetype SUBJECT title Health code BARHEALTH name Health canbedisplaysubject true ruleid BARHEALTH value BARHEALTH status modified subject BARTAKE subject|BARTAKE codetype SUBJECT title Barron's Take code BARTAKE name Barron's Take ruleid BARTAKE value BARTAKE canbedisplaybrand true status modified wordcount 452 wordcount|452 Photograph by Haley Lawrence The Medicines Company Stock Is Soaring Because Novartis Might Want to Buy It The Medicines Company Stock Is Soaring Because Novartis Might Want to Buy It The Medicines Company Stock Jumps on Report Novartis Is Exploring Acquisition

The Medicines Company stock spiked in early trading after a Bloomberg report said pharma giant Novartis was looking into a potential acquisition of the company.

The Medicines Company Up On Acquisition News

A Bloomberg report said pharma giant Novartis was looking into a potential acquisition of the company.

https://www.bloomberg.com/news/articles/2019-11-19/medicines-co-is-said-to-attract-suitors-including-novartis?utm_source=google&utm_medium=bd&cmpId=google https://www.themedicinescompany.com/investor/pr/4152740/ mailto:josh.nathan-kazis@barrons.com The Medicines Company Stock Is Soaring Because Novartis Might Want to Buy It By Josh Nathan-Kazis Photograph by Haley Lawrence

Shares of The Medicines Company, a biotech firm developing a cholesterol-lowering treatment, soared Tuesday after a Bloomberg report said pharma giant Novartis was looking into a potential acquisition of the company.

The stock was up 19.6% at $70.14 in recent trading.

The surge came just a day after shares of The Medicines Company (ticker: MDCO) jumped 12.8% on news that its key product, a so-called small-interfering RNA therapy called Inclisiran, had achieved promising results in two Phase 3 studies.

Bloomberg’s report, out early Tuesday morning, said Novartis (NVS) has been conducting due diligence on The Medicines Company in advance of a potential purchase, and that other companies have also expressed interest. The report cited “people familiar with the matter.”

A spokesman for The Medicines Company told Barron’s, “We do not comment on speculation.” Novartis didn’t immediately respond to a request for comment.

The back story. Shares of The Medicines Company have skyrocketed 206.4% so far this year as of Tuesday morning. The firm, which has no products on the market, is developing Inclisiran, which lowers so-called bad cholesterol by inhibiting the production of PCSK9 in the liver. The drug is a small interfering RNA therapy, similar to Alnylam’s (ALNY) Onpattro, which treats a nerve disease.

What’s new. The Bloomberg report comes a day after the latest in a string of promising clinical results for Inclisiran, which The Medicines Company is developing with Alnylam.

“Now with full detailed results from all three Ph.3 studies, we see Inclisiran as a potential blockbuster in the [cardiovascular] space,” wrote SVB Leerink analyst Joseph Schwartz in a note out Monday, adding that the drug is safe and convenient, with dosing just twice a year. “We believe Inclisiran could potentially see widespread uptake for the treatment and prevention of hypercholesteremia much like a yearly flu vaccine.”

Now, bigger fish seem to be circling, according to Bloomberg. The Medicines Company has a market capitalization of $5.6 billion as of Tuesday morning.

Looking forward. Shares of The Medicines Company did back off their premarket highs after the market opened. The stock had been up as much as 27% in the premarket hours.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.